Manila Times Business
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has rec
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Renk Group AG: RENK Enters Into Binding Agreement for the Sale of its Slide Bearings Business to Miba AG
Just now
Canada's Favourite Shawarma Chain Opens Its First Western Canada Location in Calgary This Sunday
Just now
BigBattery Launches NEXUS 2: 16kWh Off-Grid Solar Battery at $187/kWh
Just now
Boulder's Leslie AI Books a Record Number of Demos at NARPM 2026 National Convention
Just now